GlucoTrack, Inc. (NASDAQ:GCTK) Sees Significant Increase in Short Interest
by Jessica Moore · The Cerbat GemGlucoTrack, Inc. (NASDAQ:GCTK – Get Free Report) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totaling 883,209 shares, an increase of 1,933.7% from the March 15th total of 43,428 shares. Approximately 46.5% of the company’s shares are sold short. Based on an average daily volume of 2,982,970 shares, the short-interest ratio is presently 0.3 days.
GlucoTrack Stock Up 2.2%
GCTK stock traded up $0.01 during mid-day trading on Friday, hitting $0.66. 116,033 shares of the company were exchanged, compared to its average volume of 854,302. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.61 and a current ratio of 1.61. GlucoTrack has a 1-year low of $0.62 and a 1-year high of $15.90. The firm’s 50 day simple moving average is $1.34 and its 200 day simple moving average is $4.02. The firm has a market cap of $1.29 million, a P/E ratio of -0.01 and a beta of 0.61.
GlucoTrack (NASDAQ:GCTK – Get Free Report) last released its quarterly earnings results on Monday, March 30th. The company reported ($3.98) earnings per share for the quarter.
Hedge Funds Weigh In On GlucoTrack
A number of large investors have recently added to or reduced their stakes in GCTK. Ikarian Capital LLC acquired a new stake in shares of GlucoTrack in the 4th quarter valued at about $177,000. Boothbay Fund Management LLC acquired a new position in shares of GlucoTrack during the fourth quarter worth about $52,000. Finally, Bank of America Corp DE grew its holdings in shares of GlucoTrack by 102,125.0% during the second quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock worth $25,000 after buying an additional 4,085 shares in the last quarter. Institutional investors own 10.92% of the company’s stock.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of GlucoTrack in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.
Read Our Latest Stock Analysis on GlucoTrack
GlucoTrack Company Profile
GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.